Was wissen Sie über SGLT2-Inhibitoren, Herzinsuffizienz, neue Leitlinien und deren Umsetzung?

References

1. Huis in't Veld AE, et al. How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing. Neth Heart J. 2016;24:244-251.
2. McDonagh TA, et al; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4-131.
3. Cox ZL, et al. STRONG start for implementation of guideline-directed medical therapies. Lancet. 2022;400:1901-1903.
4. Mebazaa A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400:1938-1952.
5. Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022;28:e1-e167.
6. Packer M, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-1424.
7. McMurray JJV, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008.
8. Anker SD, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461.
9. Solomon SD, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-1098.
10. Engelhardt K, et al. Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors. Ann Pharmacother. 2021;55:543-548.
11. Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753-2786.
12. Pitt B, et al. Spironolactone for heart failure with preserved ejection fraction. New Engl J Med. 2014;370:1383-1392.
13. Solomon SD, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New Engl J Med. 2019;381:1609-1620.
14. Lund LH, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20:1230-1239.
15. Rosano GMC, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23:872-881.
16. Desai AS, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017;2:79-85.
17. Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. New Engl J Med. 2020;383:1436-1446.
18. Swedberg K, et al; RED-HF Committees and Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368:1210-1219.
19. Desta L, et al. Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction. The SWEDEHEART Registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies): a study of 199,851 patients admitted with index acute myocardial infarctions, 1996 to 2008. JACC Heart Fail. 2015;3:234-242.
20. Desta L, et al. Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: a Swedish nationwide observational study. Int J Cardiol. 2017;248:221-226.
21. Jenča D, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8:222-237.
22. Modi K, et al. Stent thrombosis. In: StatPearls. StatPearls Publishing; 2022. Updated July 25, 2022. Accessed March 3, 2023. https://www.ncbi.nlm.nih.gov/books/NBK441908/
23. Ibanez B, et al; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177.
24. O'Gara PT, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-425.
25. Gulizia MM, et al. Prevalence Of familial hypercholeSTerolaemia (FH) in Italian patients with coronary artERy disease: The POSTER study. Atherosclerosis. 2020;308:32-38.
26. Maggioni AP, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15:1173-1184.
27. Pfeffer MA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
28. Pfeffer MA, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
29. Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med. 2003;348:1309-1321.
30. Ibanez B, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation. 2013;128:1495-1503.
31. Pfeffer MA, et al. Impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial. Circulation. 2022;145:87-89.
32. Harrington J, et al. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am Heart J. 2022;253:86-98.
33. ClinicalTrials.gov. Dapagliflozin effects on cardiovascular events in patients with an acute heart attack (DAPA-MI). Accessed March 3, 2023. https://clinicaltrials.gov/ct2/show/NCT04564742